Medical Condition News

RSS

New study associates sex difference in brain with MS

A newly identified difference between the brains of women and men with multiple sclerosis (MS) may help explain why so many more women than men get the disease, researchers at Washington University School of Medicine in St. Louis report.

9 May 2014

Researchers discover new class of drugs to treat nystagmus eye condition

In another example of serendipity advancing scientific research, investigators have discovered a new class of drugs to treat an eye condition called nystagmus.

9 May 2014

BTMed, SCCA expand early lung cancer detection program for high risk construction workers

Today, the Building Trades National Medical Screening Program (BTMed) and Seattle Cancer Care Alliance (SCCA) expanded their early lung cancer detection program (ELCD) for high risk construction workers in Western Washington.

9 May 2014

Mice study shows specific energy source responsible for performing complex cognitive functions

New research suggests that certain types of brain cells may be "picky eaters," seeming to prefer one specific energy source over others.

9 May 2014

Genzyme, Isis receive 2014 Partners in Progress Corporate Award for KYNAMRO injection

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., today announced that they have received the 2014 Partners in Progress Corporate Award from NORD in recognition of KYNAMRO (mipomersen sodium) injection.

9 May 2014

Study finds ovarian cancer cells are more aggressive on soft tissues due to mechanical properties of environment

When ovarian cancer spreads from the ovaries it almost always does so to a layer of fatty tissue that lines the gut.

9 May 2014

Pharmaceutical Executive Magazine names COPAXONE therapy as 2014 "Brand of The Year"

Teva Pharmaceutical Industries Ltd., today announced that COPAXONE (glatiramer acetate injection), the #1 global therapy for relapsing multiple sclerosis, has been named the 2014 "Brand of The Year" by Pharmaceutical Executive Magazine, a leading print and online publication for the biopharmaceutical industry.

9 May 2014

St. Jude Medical presents new data on quadripolar technology at Heart Rhythm 2014

St. Jude Medical, Inc., a global medical device company, is the leader in quadripolar technology with the only cardiac resynchronization therapy (CRT) system approved in the U.S. New data presented at Heart Rhythm 2014, the Heart Rhythm Society's Annual Scientific Sessions, demonstrates increased survival, improved clinical outcomes and better cost utilization with St. Jude Medical's quadripolar technology.

9 May 2014

Neurovance reports positive results from EB-1020 SR phase 2a pilot study in adult ADHD patients

Neurovance, Inc. today announced complete results from its phase 2a pilot study of EB-1020 SR, a non-stimulant, in adult male patients with all subtypes of ADHD (attention deficit hyperactivity disorder).

8 May 2014

The Leukemia & Lymphoma Society passes $1 billion mark in blood cancer research investment

The Leukemia & Lymphoma Society announced that it has passed the $1 billion mark in research investment, a significant milestone in the cancer research landscape as LLS continues its 65 year pursuit of advancing breakthrough therapies, finding cures and ensuring access to life-saving therapies for all blood cancer patients.

8 May 2014

Sildenafil may help boys suffering from muscular dystrophy disease

Drugs used to treat erectile dysfunction may be able to slow disease progression in boys who suffer from the muscle wasting disease Duchenne muscular dystrophy.

8 May 2014

Antipsychotic medication reduces violent crime rates

People who use antipsychotic medication (such as clozapine or risperidone) to treat psychiatric illness are nearly half as likely to commit a violent crime compared to when they are not using such medication, according to new results published in The Lancet.

8 May 2014

Cellectricon, Neusentis to host webinar on phenotypic screening approaches in pain research

Cellectricon, a leading provider of advanced cell-based screening technologies and services, will co-host a webinar with Neusentis, describing the use of native cells to develop an assay with improved physiological relevance over traditional approaches in pain drug discovery research.

From Cellectricon 8 May 2014

Finding has implications for understanding cognitive decline in degenerative diseases

New research suggests that certain types of brain cells may be "picky eaters," seeming to prefer one specific energy source over others. The finding has implications for understanding the cognitive decline seen in aging and degenerative diseases such as Alzheimer's and multiple sclerosis.

8 May 2014

Hepatocellular carcinoma on the rise among Mexican Americans

Hepatocellular carcinoma (HCC), the primary cancer of the liver, is on the verge of becoming an epidemic among Mexican Americans, especially in Texas.

8 May 2014

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.

8 May 2014

Medical Condition News

New study associates sex difference in brain with MS

Researchers discover new class of drugs to treat nystagmus eye condition

BTMed, SCCA expand early lung cancer detection program for high risk construction workers

Mice study shows specific energy source responsible for performing complex cognitive functions

Genzyme, Isis receive 2014 Partners in Progress Corporate Award for KYNAMRO injection

Study finds ovarian cancer cells are more aggressive on soft tissues due to mechanical properties of environment

Pharmaceutical Executive Magazine names COPAXONE therapy as 2014 "Brand of The Year"

St. Jude Medical presents new data on quadripolar technology at Heart Rhythm 2014

Neurovance reports positive results from EB-1020 SR phase 2a pilot study in adult ADHD patients

The Leukemia & Lymphoma Society passes $1 billion mark in blood cancer research investment

Sildenafil may help boys suffering from muscular dystrophy disease

Antipsychotic medication reduces violent crime rates

Cellectricon, Neusentis to host webinar on phenotypic screening approaches in pain research

Finding has implications for understanding cognitive decline in degenerative diseases

Hepatocellular carcinoma on the rise among Mexican Americans

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Smartphone app shows promise for detecting early signs of mood changes in people with bipolar disorder

Shuganjieyu capsule reverses depressive behaviors by increasing brain-derived neurotrophic factor

Children who wheeze are at risk of developing damage that affect lung function

RAAV/ABAD-DP-6His generates fusion peptide that protects PC12 cells from oxidative stress injury

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News